Patents by Inventor Denette K. Murphy

Denette K. Murphy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline forms of a factor Xa inhibitor
    Patent number: 7388096
    Abstract: The instant invention provides crystalline forms of 1-(3-chlorophenyl)-7-oxo-6-[4-(2-oxo-1 (2H)pyridinyl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide and its solvates thereof; processes for the production of such crystalline forms; pharmaceutical compositions comprising such crystalline forms; and methods of treating thromboembolic disorders with such crystalline forms or such pharmaceutical compositions.
    Type: Grant
    Filed: September 26, 2005
    Date of Patent: June 17, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Margaret M. Gleeson, Gary McGeorge, Bang-Chi Chen, Huiping Zhang, Mary F. Malley, John D. DiMarco, Denette K. Murphy, Xiaotian Yin, Steven R. Fabian, Jasmine M. Gupta
  • Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators
    Patent number: 6417394
    Abstract: This invention pertains to novel salt forms of trophenylethylene compound, such as 3-[4(1,2-diphenyl-but-1-enyl)-phenyl]-acrylic acid, as selective estrogen receptor modulators. This invention also provides methods for the treatment and/or prevention of breast, uterine, ovarian, prostrate and colon cancer, osteoporosis, cardiovascular disease, and benign proliferative disorders, as well as pharmaceutical compositions of the compounds of the present invention.
    Type: Grant
    Filed: April 3, 2001
    Date of Patent: July 9, 2002
    Assignee: Bristol Myers Squibb Pharma Company
    Inventors: Gary A. Cain, Reginald O. Cann, Christopher A. Teleha, Denette K. Murphy
  • Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators
    Publication number: 20020004496
    Abstract: This invention pertains to novel salt forms of trophenylethylene compound, such as 3-[4(1,2-diphenyl-but-1-enyl)-phenyl]-acrylic acid, as selective estrogen receptor modulators. This invention also provides methods for the treatment and/or prevention of breast, uterine, ovarian, prostrate and colon cancer, osteoporosis, cardiovascular disease, and benign proliferative disorders, as well as pharmaceutical compositions of the compounds of the present invention.
    Type: Application
    Filed: April 3, 2001
    Publication date: January 10, 2002
    Inventors: Gary A. Cain, Reginald O. Cann, Christopher A. Teleha, Denette K. Murphy